Amelioration of Amyotrophic Lateral Sclerosis in SOD1<sup>G93A</sup> Mice by M<sub>2</sub> Microglia from Transplanted Marrow

MICHAEL W. EPPERLY<sup>1</sup>, RENEE FISHER<sup>1</sup>, LORA RIGATTI<sup>2</sup>, SIMON WATKINS<sup>3</sup>, XICHEN ZHANG<sup>1</sup>, WEN HOU<sup>1</sup>, DONNA SHIELDS<sup>1</sup>, DARCY FRANICOLA<sup>1</sup>, HULYA BAYIR<sup>4</sup>, HONG WANG<sup>1</sup>, STEPHANIE THERMOZIER<sup>1</sup>, ANDREW HENDERSON<sup>1</sup>, CHRISTOPHER DONNELLY<sup>5</sup>, PETER WIPF<sup>6</sup> and JOEL S. GREENBERGER<sup>1</sup>

<sup>1</sup>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, U.S.A.;<br /><sup>2</sup>Division of Laboratory Animal Resources (DLAR), University of Pittsburgh, Pittsburgh, PA, U.S.A.;<br /><sup>3</sup>Department of Cell Biology and Center for Images, University of Pittsburgh, Pittsburgh, PA, U.S.A.;<br /><sup>4</sup>Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, U.S.A.;<br /><sup>5</sup>Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA, U.S.A.;<br /><sup>6</sup>Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, U.S.A.

**Abstract.** Background/Aim: The cause of fatal neuromuscular amyotrophic lateral sclerosis (ALS) is not known. Materials and Methods: Ninety-day-old superoxide-dismutase-1<sup>G93A</sup> (SOD1<sup>G93A</sup>) mice demonstrating level 1 paralysis, received 9.0 Gy total body irradiation (TBI) from a cesium source at 340 cGy per minute, and intravenous transplantation with 1×10<sup>6</sup> C57BL/6 green fluorescent protein (GFP)+ donor bone marrow cells. Results: Paralysis-free survival was prolonged in TBI and bone marrow-transplanted SOD1<sup>G93A</sup> mice from 100 to over 250 days (p=0.0018). Other mice transplanted with SOD1<sup>G93A</sup> marrow or marrow treated with the free-radical scavenger MMS350 showed no therapeutic effect. GFP+ macrophage-2 (M<sub>2</sub>) microglial cells of bone marrow origin, were seen at sites of degenerating anterior horn motor neurons. SOD1<sup>G93A</sup> mice had a disruption in the blood–brain barrier permeability which was reversed by marrow transplant from C57BL/6 mice. SOD1<sup>G93A</sup> marrow showed unexpected robust hematopoiesis in vitro, and radioresistance. Conclusion: After TBI, M<sub>2</sub> microglial cells from transplanted donor marrow extended the paralysis-free interval in SOD1<sup>G93A</sup> mice.

This article is freely accessible online.

**Correspondence to:** Joel S. Greenberger, MD, Professor and Chairman, Department of Radiation Oncology, UPMC Hillman Cancer Center, UPMC Cancer Pavilion, Rm. 533, 5150 Centre Avenue, Pittsburgh, PA 15232, U.S.A. Tel: +1 4126473602, Fax: +1 4126476029, e-mail: greenbergerjs@upmc.edu

**Key Words:** Total body irradiation, ALS, marrow origin, spinal cord M<sub>2</sub> cells.
neurons represents multiple phases in the degenerative process, one inflammatory potentially initiating the disease process (28), and a second response to degenerating neurons with a production of repair-related cytokines (9, 10). There remains controversy over the interaction of glial cells with motor neurons in the development of paralysis (57, 58).

In the present studies, we tested the hypothesis whether cells of donor bone marrow origin might provide a therapeutic effect if delivered to SOD1G93A mice after total body irradiation (TBI).

Materials and Methods

Mice and animal care. SOD1G93A and control SOD1 transgenic mice containing 4 copies of normal human SOD1 gene were obtained from the Jackson Laboratories, Bar Harbor, Maine. SOD1G93A-green fluorescent protein (GFP+) mice were bred according to published methods used to breed SMAD family member 3 (Smad3)−/− Fanconi anemia group D2 (FancaD2)−/− mice (59). Mice were derived from breeding pairs of SOD1G93A and control mice. Female mice were housed at five mice per cage and male mice four per cage according to institutional regulations. Mice were fed standard Purina laboratory chow. All work was performed under protocol 18022000, approved by the University of Pittsburgh Institutional Care and Use Committee. Veterinary care was provided by the Division of Laboratory Animal Resources at the University of Pittsburgh.

Paralysis was scored as described by Hatzipetros et al. (26). Mice were euthanized when reaching paralysis with neurological score (NS) of 3. At NS 3, the mice still have complete use of their front legs but show paralysis in the rear leg. Mice with NS 1 have no paralysis but exhibit some trembling in the rear legs and a collapsing of the rear legs toward the lateral mid line when picked up. NS 2 paralysis reflects the beginning of paralysis in the rear legs with a complete collapse of the rear legs to the lateral midline when picked up; mice begin to show an altered gait but are still able to move easily around in the cage.

Mice were given no irradiation, 9 Gy, or 7.0 Gy TBI using a Shephard Mark I 137Cs γ-ray source (J. L. Shepherd, San Fernando, CA, USA), according to published methods (59). Other mice received 9 Gy cranial spinal irradiation. Subgroups were given 106 cells from B6 GFP+ or wild-type B6 mouse marrow intravenously after fractionated TBI, as described elsewhere (60).

TBI and craniospinal irradiation. Female and male mice received 9.0 Gy TBI from a cesium source at 340 cGy/min using a Shephard Mark 1 irradiator (J.L. Shepherd, San Fernando, Ca, USA). Bone marrow was isolated from C57BL/6 GFP+ mice (Jackson Laboratories, Bar Harbor, ME, USA). The irradiated SOD1G93A mice were injected intravenously with 1x106 C57BL/6 GFP+ donor bone marrow cells. Chimerism was determined from the presence of GFP+ cells in peripheral blood according to (60). The mice were followed for the development of NS 3 paralysis at which time they were sacrificed and the spinal cord was isolated and fixed in 2% paraformaldehyde (PFA). Some of the spinal cords were analyzed by single photon, confocal, ribbon-scanning microscopy for quantitation of bone marrow origin cells. Other spinal cords were fixed in 2% PFA, sectioned, and stained for M1 and M2 microglial cells.

Control C57BL/6NTac mice were transplanted at the same age with SOD1G93A ALS bone marrow under the same conditions and followed for development of paralysis. To determine if spinal cord irradiation alone without bone marrow transplantation altered the development of paralysis, SOD1G93A mice were irradiated with 9.0 Gy to the spinal cord and brain while shielding the remainder of the body. All mice were followed for the development of paralysis. In a separate group of SOD1G93A mice, marrow transplant using B6 GFP+ or SOD1G93A GFP+ 1x106 bone marrow cells was performed at 24 h after TBI.

To determine if TBI alone delay paralysis, SOD1G93A mice were irradiated to 7.0 Gy TBI without bone marrow transplantation. Mice were followed for development of paralysis.

Treatment with MMS350. The water-soluble radiation mitigator MMS350 was produced in the laboratory of Dr. Peter Wpif at the University of Pittsburgh, Pittsburgh, PA, USA and was administered at 400 mg/ml to mice in drinking water as described (61, 62) over days 60 until death from paralysis.

Continuous bone marrow culture. Long-term bone marrow cultures (LTBMCs) were established from the femur and tibia marrow of SOD1G93A or control transgenic mice, as described previously (63). The contents of a femur and tibia (N=6/genotype) were flushed into McCoy’s 5A medium (Gibco, Gaithersburg, MD, USA) supplemented with 25% horse serum (Cambrex, Rockland, ME, USA) and 10−3 M hydrocortisone sodium hemisuccinate. Cultures were incubated at 33°C in 7% CO2. After 4 weeks, horse serum was replaced with 25% fetal bovine serum (FBS) (Gibco, Gaithersburg, MD, USA) (63). The cultures were observed weekly for hematopoietic cell production and cobblestone island formation. The number of cobblestone islands of 50 cells or more were scored weekly in each flask (63-64). Two-sided two-sample t-test was used to compare the number of cobblestone islands between culture groups each week. p-Values less than 0.05 were regarded as significant.

The cultures were observed weekly for hematopoietic cell production and adherent cell layer confluence. Non-adherent cell production data were expressed as the mean±SEM standard deviation of the mean (SEM) of weekly non-adherent cell number and cumulative non-adherent cell production. Confluence data were expressed as the mean±SEM of the percentage adherent cell layer confluence.

Establishment of clonal bone marrow stromal cell lines. Adherent cell layers from one 4-week-old LTBMC from SOD1G93A (63-64) and control mice were trypsinized and expanded by passage into Dulbecco’s Modified Eagle’s Medium (DMEM) with10% FBS to establish bone marrow stromal cell lines according to published methods (63). Cells were passaged for 10 weeks to establish cell lines. Culture were incubated at 37°C in 5% CO2.

Hematopoietic colony-forming cell lines and fresh marrow colony assays. Each week after explant and establishment of LTBMCs, 1x105 nonadherent cells were plated in triplicate in methylcellulose-containing medium, as previously published (63). Cells were incubated at 37°C in 5% CO2. At day 7 after plating, colonies of ≥50 cells were counted. The plates scored at day 7 were returned to the incubator for scoring at day 14. Data for days 7 and 14 are presented as the mean±SEM of weekly colony-forming cells and cumulative colony-forming cells (63).
Establishment of bone marrow stromal cell lines. Adherent cell layers from one LTBMC per treatment group were trypsinized and expanded by passage into DMEM supplemented with 10% FBS to establish bone marrow stromal cell lines according to published methods (63). Established criteria were used for authentication of cell lines (63). Genotyping of all bone marrow stromal cell lines established they were indeed from the SOD1<sup>G93A</sup> or control genotype. The established lines maintained stromal cell features including capacity for osteoblast differentiation, and support of hematopoietic cells in co-culture. We documented cell surface phenotype, biology, and absence of capacity to differentiate into hematopoietic cells. These cell lines were characterized as bone marrow stromal cells or mesenchymal stem cells (63). Cell lines were incubated at 37°C in 5% CO₂ and passaged for 10 weeks to establish cell lines.

Establishment of single-cell-derived clonal marrow stromal cell lines. Single-cell cloning experiments were performed using fresh marrow, an adherent cell layer from a LTBMC at week 13 after explant, and bone marrow stromal cell lines that were established as described (63). Flow cytometry was used to sort single cells into the wells of a 96-well plate. Cells were grown in DMEM supplemented with 20% FBS, 1% antibiotic-anti-mitotic solution, and 1% L-glutamine. Plates were observed weekly for growth. Clonal lines were established from wells that showed growth after single-cell plating.

Histochemistry and ribbon scanning, confocal single-photon microscopy. The detailed methods for the microscopy techniques of the spinal cord have been published in the web-based textbook (65).

Microbead assay for blood–brain barrier permeability. Blood–brain barrier permeability was analyzed by intravenous perfusion with 0.2 µm Fluorospheres (F8810; Invitrogen) on day 125 in control SOD1<sup>G93A</sup> mice, SOD1<sup>G93A</sup> mice transplanted on day 90 with GFP+ C57BL6 bone marrow and C57BL/6 mice.

Immunofluorescence assay for detection of astrocytes, neurons, glial cells, and immunocytes. Spinal cord was removed from control C57BL/6 mice, and SOD1<sup>G93A</sup> mice with phase1, phase 2 and phase 3 paralysis. The spinal cords were fixed in 2% paraformaldehyde (PFA; Thermo Fisher Scientific, Waltham, MA, USA), sectioned, and stained with antibodies to astrocytes, neurons, glial cells and immunocytes. The antibodies used, their vendor/supplier and cellular target function are shown in Table 1. Secondary antibodies used include goat anti-rabbit and donkey anti-goat (Thermo Fisher Scientific, Waltham, MA, USA). The antibodies specific for astrocytes, motor neurons, M<sub>1</sub> and M<sub>2</sub> microglial cells, endothelial cells, and hematopoietic cells have been described elsewhere (65). Cells were incubated with primary antibody mixture overnight at 4°C then washed with PBS three times for 5 min each. Secondary antibody solution was prepared at manufacturer-suggested dilutions in PBS and added to cells for 1 hour at room temperature. After washing with PBS three times for 5 min each, 0.5 µg/ml 4',6-diamino-2'-phenylindole dihydrochloride (DAPI; Millipore Sigma, St. Louis, MO, USA) in PBS was added for 10-20 min at room temperature to label nuclei. Cells were mounted and allowed to dry for 30 min. Pictures were taken using fluorescence microscopes at the University of Pittsburgh Center for Biologic Imaging. For each sample, three fields were subjected to analysis. Data are presented as the mean±standard error of the percentage of cells staining positively for the target protein.

Statistical analysis. For in vivo experiments, the mean and standard error of the mean for each group was determined and graphed using GraphPad Prism (GraphPad Software, LaJolla, CA, USA) to compare experimental groups. Student’s unpaired t-test was used to compare data of each group at different time points to those for the control group, as well as to compare all days for each experimental group (including the control) to day 0 (non-irradiated baseline) of the control group.

For LTBMCs, GraphPad Prism (GraphPad Software) was used for statistical analysis and plotting graphs. Graphs were plotted using the mean±SEM. The data were analyzed using two-tailed Student’s t-test. In this exploratory experiment, p-values were not corrected for multiple comparisons. Differences were considered significant at p<0.05 (27). At each week of LTBMC for each of the endpoints (i.e. weekly non-adherent cells per flask, percent confluençe, day-7 colonies, and day-14 colonies), data were summarized with mean±standard deviation. Comparisons were made using the one-way analysis of variation (ANOVA) F-test at each time point, followed by Tukey’s multiple comparisons.

The description of calculation of D<sub>0</sub>, which is the irradiation dose required to reduce survival to 37% on the linear portion of the survival curve, and α, which represents the shoulder on the survival curve as calculated by the back extrapolation of the linear portion of the survival curve to the y axis, for radiation survival curves has been published in detail elsewhere (63).

Results

Establishment of bone marrow chimeric GFP+ SOD1<sup>G93A</sup> mice. After marrow transplant, as described in the Materials
and Methods, blood samples were checked for chimerism at day 60 and 90. Mice with over 80% donor origin GFP+ cells were considered to be successfully transplanted.

Quantitation of TBI and bone marrow transplantation delayed hind limb paralysis. TBI and marrow transplant significantly delayed paralysis and extended survival of SOD1(G93A) mice (Figure 1A). TBI plus normal marrow transplant but not sub-TBI, reduced TBI dose, transplant of SOD1(G93A) donor marrow nor administration of MMS350 prolonged the paralysis-free interval (p<0.0039) (Figure 1B).

The stages of paralysis are shown histologically in Figure 2. Bone marrow-derived M2 microglia were found in the spinal cords of SOD1(G93A) mice transplanted with GFP+ donor marrow at 120 days of age when other groups are developing stage 3 paralysis (Figure 3). GFP+ cells were seen throughout the spinal cord (Figure 4). The blood–brain barrier was permeable to microbeads in non-irradiated and non-transplanted SOD1(G93A) mice (Figure 5) confirming findings of a prior publication (47). In contrast, TBI-treated, then GFP+ marrow-transplanted mice showed correction of the blood–brain barrier defect (Figure 5). Control wild-type mice transplanted with SOD1(G93A) bone marrow demonstrated no paralysis (Figure 1A). There was no transfer of cells of SOD1(G93A) GFP+ donor marrow origin to the spinal cord of wild-type recipients. The blood–brain barrier was no longer disrupted in TBI-treated normal marrow-transplanted SOD1(G93A) mice (Figure 5).

The results show that TBI and bone marrow transplantation significantly extended the survival of SOD1(G93A) mice, and was a robust neuroprotective and translatable strategy to prevent motor neuron degeneration starting at the time of NS1 paralysis in SOD1(G93A) mice (Figure 1).

Analysis of subsets of cells of bone marrow origin in spinal cord of TBI-treated and bone marrow-transplanted SOD1(G93A) mice. We identified microglia from GFP+ marrow origin in the spinal cords of SOD1(G93A) TBI/marrow-transplanted mice (Figures 3 and 4). We tested whether there were GFP+ M2 microglial cells in the anterior horns of the spinal cords at days 120, 200, and 280 in GFP+ marrow-transplanted SOD1(G93A) mice (Figure 3). The spinal cord showed significant infiltration with GFP+ cells of marrow origin at multiple levels (Figures 3 and 4). We did not see cells of marrow origin in the spinal cords of TBI-treated wild-type C57BL/6 mice that were transplanted with GFP+ SOD1(G93A) marrow.

Demonstration of reversal of blood/brain barrier permeability in SOD1(G93A) mice. SOD1(G93A) mice demonstrated the blood–brain barrier was permeable to 2-μm diameter beads (Figure 5), confirming previous findings (47). In contrast, control C57BL/6 mice and C57BL/6 mice that
had been transplanted with SOD1<sup>G93A</sup> marrow showed no such detectable blood–brain barrier permeability (Figure 5).

Failure of isolated craniospinal irradiation and of sub-lethal TBI with no marrow transplant to prolong the paralysis-free interval in SOD1<sup>G93A</sup> mice. As shown in Figure 1B, SOD1<sup>G93A</sup> mice treated with 9.25 Gy to the brain and spinal cord only while shielding the rest of the body, and those receiving 7.0 Gy TBI without marrow transplant showed no therapeutic effect. Furthermore, SOD1<sup>G93A</sup> mice treated with radiation mitigator MMS350 in drinking water starting at day 60 showed no therapeutic effect (Figure 1B).

---

Figure 2. Histopathological stages of spinal cord motor neuron loss in superoxide dismutase-1 (SOD1)<sup>G93A</sup> mice (H&E ×20). With the advancement of each stage, there was increased degeneration and loss of motor neurons, astrogliosis in the areas of motor neuron loss, and vacuolation within the gray matter (n=3 at each stage). Lesions were more pronounced in the ventral horns (bar=100 μm).

Figure 3. Histochemical detection of M<sub>2</sub> microglial cells of bone marrow origin in the spinal cord of superoxide dismutase-1 (SOD1)<sup>G93A</sup> mice. A: Cross section of spinal cord at recipient age 120 days which is 30 days post irradiation and transplantation of green fluorescent protein (GFP)+ bone marrow cells (n=3). Labelling is glial fibrillary acidic protein (GFAP) (red), nuclei (blue), ionized calcium-binding adapter molecule 1 (white), and stem cells (green). There is almost complete co-localization between the green cells of marrow origin and the white M<sub>2</sub> microglia (×100). B and C: Boxed inset region from A showing M<sub>2</sub> microglia (B) overlaying exactly with the GFP-labeled cells (C), highlighted with yellow arrows. Bar=500 μm (×500).
Hematopoiesis in LTBMCs from SOD1<sup>G93A</sup> mice. We tested the effect of the SOD1<sup>G93A</sup> genotype on limiting the duration of hematopoiesis in LTBMCs as a marker of defective antioxidant capacity according to prior publications (59, 61-64). Unexpectedly, SOD1<sup>G93A</sup> mouse marrow had greater longevity than did that from SOD1 transgenic control mice. Stability of the adherent layer was equivalent in SOD1<sup>G93A</sup> and SOD1 transgenic control mice (Figure 6A).

**Figure 4.** Rendered three-dimensional image of superoxide dismutase-1 (SOD1)<sup>G93A</sup> murine spinal cord following irradiation and transplantation of green fluorescent protein (GFP)<sup>+</sup> bone marrow cells. Images were collected following CUBIC clearing and imaging using a Caliber XT ribbon scanning confocal microscope (25× 1.15 NA water objective, WD 2.4 mm) (n=3). A: En face reconstruction of the raw image. GFP<sup>+</sup> cells can be seen throughout the tissue, but are more concentrated in the lumbar region in the lateral nerve branches. B: The GFP<sup>+</sup> cells in the same image set in which the positive structures are highlighted as green spheres. C: The 3D nature of the reconstruction is clearly visible. Bar=1 cm. (Link to movie of Figure 4).

**Figure 5.** The blood–brain barrier is permeable in superoxide dismutase-1 (SOD1)<sup>G93A</sup> mice. A: Section though spinal cord of an ALS mouse (age 100 days) perfused with 0.2 μm Fluospheres (F8810, Invitrogen) shown in red (n=3). The actin cytoskeleton is green and blue defines the nuclei (bar=250 μm). Beads are present throughout the soma of the spinal cord (Panel B). However, in TBI/transplanted mouse at 30 days post transplantation (Panel C) no beads are present in the spinal cord.
Stem cell islands, cobblestones, were significantly greater in number (Figure 6B). There was a significantly greater production of total hematopoietic cells (Figure 6C), and greater duration of production of total cell forming day 7 (Figure 6D) and day 14 (Figure 6E) colony-forming progenitors (Supplemental Tables I-V may be found at https://pitt.box.com/s/ajzj6ov2cw9ttrbnspnfz3p7d7so7mob).

Radiation resistance of clonal bone marrow stromal cell lines from SOD1\(^{G93A}\) mice. In prior studies, greater longevity of hematopoiesis in LTBMCs correlated with radioresistance of hematopoietic progenitors, suggesting a greater capacity of cells to tolerate oxidative stress (63). The data revealed that both SOD1\(^{G93A}\) mouse isolated bone marrow CFU-GEM (Figure 7A, Table II) and marrow culture-derived stromal cell lines (Figure 7B, Table II) were radioresistant.

Number of motor neurons in thoracic and lumbar spinal cord of SOD1\(^{G93A}\) mice is reduced compared to controls. The increased number of hematopoietic progenitor cells in LTBMCs and radioresistance of both fresh marrow colony-forming units-granulocyte, erythrocyte, monocyte, megakaryocyte and stromal cells from SOD1\(^{G93A}\) mice suggested that the defective SOD1 gene may not have reduced stem cell numbers in the marrow, but may have depleted the critical motor neurons in the spinal cord.

We counted motor neurons in spinal cords from mice of the SOD1\(^{G93A}\) genotype in NS 0, 1, 2, 3. While the number of motor neurons was reduced at NS 1, 2, and 3 compared to stage 0, there was no clear direct stage-specific loss of motor neurons with progression of paralysis (Figure 8).

Discussion

In the present study with SOD1\(^{G93A}\) ALS mice, we demonstrated that TBI and bone marrow transplantation during the symptomatic stage of the disease (day 90) exerted a profound therapeutic effect by delaying paralysis, and extending survival two-fold from 120 to over 250 days. This treatment regimen was significantly more effective than previous mesenchymal stem cell or bone marrow transplantation studies in SOD1\(^{G93A}\) mice, and in other models of ALS (51-52). The present treatment paradigm more accurately recapitulates a therapeutic approach in patients with ALS since they often exhibit symptoms at the time of diagnosis. In other studies, from our laboratory using marrow transplant at day 60 before symptoms, we observed that the prolongation of survival was even better (data not shown). We found that SOD1\(^{G93A}\) mice, but not transgenic mice with four copies of normal human SOD1 displayed permeability of the blood–brain barrier, which was reversible by TBI and marrow transplant, and we identified bone marrow-derived M2 microglia at the site of spinal motor neurons.

The present data suggest that the observed therapeutic effect of TBI and marrow transplant is mediated by M2 microglia of marrow origin. In the present experiments, TBI and marrow transplant producing chimeric SOD1\(^{G93A}\) mice resulted in M2 microglial cells of bone marrow origin accumulating at the site of anterior horn cell degeneration. Mice receiving 9.0 Gy craniospinal irradiation or sub-lethal 7.0 Gy TBI irradiation alone did not show a therapeutic effect. Continuous antioxidant treatment with MMS350 (61,62) in drinking water also showed no beneficial effect.

Our data are the first to be reported of successful TBI and bone marrow transplantation in symptomatic SOD1\(^{G93A}\) mice. Treatment did delay paralysis and more than doubled the lifespan. We determined that sub-lethal TBI, cranial spinal, or of the spinal cord only was not therapeutic. A marrow cell population facilitated accumulation of therapeutic M2 microglial cells of marrow origin in the spinal cord at the site of motor neuron, but only after TBI. These studies are the first to demonstrate that ionizing irradiation in TBI is therapeutic for ALS.

Our novel SOD1\(^{G93A}\) GFP+ mice and our unique single-photon, confocal ribbon-scanning microscopy allowed us to count all green motor neurons in the entire spinal cord. We have constructed a jig which allows non-anesthetized immobilized mice to be irradiated in specific areas of the spinal cord with precise radiation doses. In this way, less than 1% of the prescribed dose is delivered outside the irradiated field using our Stereotactic Radiosurgery Unit at our TrueBeam/Varian linear accelerator. The combination of

### Table II. Radioresistance of superoxide dismutase-1 (SOD1)\(^{G93A}\) isolated bone marrow and bone marrow stromal cells.

| Mouse Strain          | SOD1\(^{G93A}\) bone marrow cells | SOD1\(^{G93A}\) bone marrow stromal cells |
|-----------------------|-----------------------------------|------------------------------------------|
|                       | Do (Gy)                           | n                                        | Do (Gy) | n          |
| SOD1 Transgenic       | 7.583±0.819                       | 1.554±0.0598                             | 8.564±1.564 | 1.319±0.0799 |
| SOD1\(^{G93A}\)       | 4.791±0.5162                      | 1.593±0.01132                            | 3.803±0.3985 | 1.653±0.07226 |
| p-Value               | 0.0488                            |                                          | 0.0210  | 0.0228     |
these novel techniques allowed us to quantitate the effect of each of the treatment modalities on preserving the number of intact and non-degenerating anterior horn motor neuron cells. Only TBI plus bone marrow transplantation facilitated the therapeutic effect in these SOD1\textsuperscript{G93A} mice.

TBI for preparation of recipients for marrow transplant has been used for over 60 years in the treatment of not only cancer, but also autoimmune diseases and genetic disorders, including some that affect the central nervous system (49, 50). Use of bone marrow transplant in ALS has not been successful since results showed either no effect (51), or minimal effect (52). Irradiation effects on the spinal cord and the radiobiology of neurons have not been considered as a possible therapeutic modality for diseases of motor neurons in ALS (53). The role

Figure 6. Continued
of cells of marrow origin, both pro-inflammatory and anti-inflammatory, in the clinical evolution of ALS has not been mechanistically coupled with the role of irradiation relative to abnormalities in the blood–brain barrier in ALS, nor have the effects of transplanted marrow cells into patients with ALS been studied relative to prolongation of the paralysis-free interval (36, 41, 47, 54-58, 66-69).

Recent data with SOD1<sup>G93A</sup> mice suggest that the inflammasome and significantly, interleukin 1 family cytokines, may mediate motor neuron cell death via induction of radical oxygen species pathways (70-78). How M<sub>2</sub> microglial from marrow might neutralize these interactions at the level of the microglial cell to motor neuron interface is unknown. Because 10% of ALS cases are familial, these SOD1<sup>G93A</sup> mice may represent the most appropriate genetic model for future ALS studies.

The mechanism of cell death in ALS motor neurons is not known. Apoptosis, necroptosis, ferroptosis, parthanatos, and pyroptosis may be occurring. The role of M<sub>1</sub> microglial cells in initiating motor neuron destruction and M<sub>2</sub> cells in ameliorating destruction is unknown. Use of TBI and bone marrow transplantation might be possibly in other neurodegenerative diseases including: multiple sclerosis, frontotemporal dementia, and the multiple etiologies of sporadic ALS such as that following trauma.

SOD1<sup>G93A</sup> mice receiving bone marrow transplant at day 60 before onset of signs of paralysis fared much better, but translation of these data to the clinic is not practical since diagnosis of ALS is made after the onset of symptoms and weakness. Our mouse data do suggest that the course of degeneration might be further interrupted by earlier bone marrow transplantation. The mechanisms for blood–brain

Figure 6. Improved hematopoiesis in long-term bone marrow cultures from superoxide dismutase-1 (SOD1)<sup>G93A</sup> mice compared to control SOD1 transgenic mice containing four copies of the normal human transgene (SOD1 transgene) (n=4). Absolute and cumulative data for surface area confluence (A), cobblestone islands per flask per week (B), non-adherent cells produced per flask per week (C), and colony-forming cells generated per flask per week at day 7 (D) and day 14 (E). All statistical analysis for the data is shown in Supplementary Tables I to V (https://pitt.box.com/s/ajj6ov2cw9trbunpxj3p7d7s7m7m).
barrier permeability in ALS, and its restoration by marrow transplant is at present not known.

The unexpected prolongation of LTBMC hematopoiesis and the radioresistance of cell lines and fresh marrow from SOD1<sup>G93A</sup> mice appears to be unrelated to motor neuron defects in these same mice. SOD1<sup>G93A</sup> mice with four copies of the mutant gene compared to copies of the normal human gene showed no increase in duration of hematopoiesis in LTBMCs, and cell lines were not radioresistant. The defective SOD1 may have caused changes in the bone marrow resulting in the up-regulation of SOD2, glutathione, or glutathione peroxidase-4 that may explain the differences in bone marrow biology in SOD1<sup>G93A</sup> mice.

TBI combined with bone marrow transplantation is a potentially valuable therapeutic option for treating ALS. The subset of donor bone marrow cells (hematopoietic stem cells, committed granulocyte/macrophage progenitors, or mesenchymal stem cells) required to provide the therapeutic effect must also be determined (59, 60, 63, 64, 79-82).

Lrcc33−/− mice lack central nervous system vascular abnormalities. These mice have a different transformed growth factor-beta, develop ascending paraparesis and death attributable to microglia activation. Recently it was

Figure 7. Radiation resistance of fresh marrow hematopoietic progenitor cells from superoxide dismutase-1 (SOD1)<sup>G93A</sup> mice (n=3) (A) and bone marrow stromal cell lines from SOD1<sup>G93A</sup> and SOD1 transgenic (B6) mice (B). Radiation survival curves were carried out as described in the Materials and Method. The data are a composite of data from 3-6 experiments.

Figure 8. Stages of spinal cord paralysis in superoxide dismutase-1 (SOD1)<sup>G93A</sup> mice. Marrow-transplanted and control SOD1<sup>G93A</sup> mice were sacrificed when developing amyotrophic lateral sclerosis with neurological score (NS) 0, 1, 2 or 3 paralysis (n=3). The spine was removed from euthanized mice, and the spinal cord was flushed from the vertebral column, fixed for 2 h in 2% paraformaldehyde, and then stored in 30% sucrose for 24 h. The number of neurons in sections at each stage of paralysis was normalized by dividing the number of neurons by the number of nuclei.
demonstrated that transplantation of donor bone marrow from a wild-type mouse ameliorated these abnormalities due to the migration of wild type bone marrow origin microglia from the bone marrow (75). These data are a further indication in another model system that microglia arising from transplanted marrow can ameliorate a spinal cord degenerative disorder. Microglia appears to be a central component of the pathophysiology of ALS, as well as other neurodegenerative disorders (76), and bone marrow transplants may provide a cellular mechanism to correct such defects.

Supplemental Data

All supplemental data may be found at https://pitt.box.com/s/ajzj6ov2cw9ttbnsnlfz3p7d7so7mob

Conflicts of Interest

The Authors have no conflicts of interest in regard to this study.

Authors’ Contributions

Michael Epperly, Ph.D., supervised all experiments. Joel Greenberger, M.D., planned and reviewed data for every experiment. Stephanie Thermozier scored radiation survival assay, and slides for immunostaining. Lora Rigatti, VMD, reviewed histopathology of spinal cords. Xichen Zhang, MD, carried out analysis of genotyping. Donna Shields carried out long-term bone marrow cultures. Wen Hou carried aided in staining of slides. Renee Fisher carried out all animal breeding and genotyping, and, also, observed animals daily and documented stages of paralysis. Simon Watkins, Ph.D., prepared fluorescent images. Andrew Henderson carried out the analysis of the numbers of neurons in spinal cords. Darcy Franicola carried out the assays for antioxidants and radiation survival curves of cell lines and fresh marrow. Christopher Donnelly, Ph.D., carried out review of all data, planned experiments in collaboration with radiation oncologists, and served as the neurosciences contributor for analysis and interpretation of all data. Hong Wang, Ph.D., completed all the biostatistics for the article. Hulya Bayir, M.D., analyzed histopathology and stages of paralysis. Peter Wipf, Ph.D., prepared drugs tested in Figure 9.

Acknowledgements

This study was supported by NIH U19-A1068021 grant. Presented at the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, October, 2018, San Antonio, TX, USA.

References

1 Haverkamp LJ, Appel V and Appel SH: Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118(pt3): 707-719, 1995. PMID: 7600088.

2 Boillee S, Vande Velde C and Cleveland DW: ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52(1): 39-59, 2006. PMID: 17015226.

3 Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’Regan JP and Deng HX: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364(6435): 362, 1993. PMID: 8446170. DOI: 10.1038/362059a0

4 Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Bellerocche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G and Shaw CE: TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870): 1668-1672, 2008. PMID: 18309045. DOI: 10.1126/science.1154584

5 Vance C, Rogelj B, Hortobagyi T, De Vox KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Bellerocche J, Gallo JM, Miller CC and Shaw CE: Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323(5918): 1208-1211, 2009. PMID: 19251628. DOI: 10.1126/science.1165942

6 Kwiatkowski, Jr TJ, Bosca DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE and Brown RH Jr.: Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323(5918): 1205-1208, 2009. PMID: 19251627. DOI: 10.1126/science.1166066

7 Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, Zheng JG, Shi Y, Siddique N, Arrat H, Donkervoort S, Ajroud-Driss S, Sufit RL, Heller SL, Deng HX and Siddique T: SQT5/1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68(11): 1440-1446, 2011. PMID: 22084127. DOI: 10.1001/archneurol.2011.250

8 Turner, MR, Cagnin A, Turkheimer FE, Miller CCJ, Shaw CE, Brooks DJ, Leigh PN and Banati RB: Evidence of widespread cerebral microglia activation in amyotrophic lateral sclerosis: An [11C] ®-PK11195 positron emission tomography study. Neurobiol Dis 15: 601-609, 2004. PMID: 15056468.

9 Lall D and Baloh RH: Microglia and C9orf72 in neuroinflammation and ALS. J Neuroinflammation 12: 24, 2015. PMID: 26373506. DOI: 10.1186/s12974-015-0067-9

10 Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, Keren-Shaul H, Gury M, Lara-Astaiso D, Thaiss CA, Cohen M, Bahar Halpern K, Lorenzo-Vivas E, Itzkovitz S, Elinav E, Sieweke MH, Schwartz M and Amit I: Microglia development follows a stepwise program to regulate brain homeostasis. Science 353(6301): aad8670, 2016.

11 Town T, Nikolic V and Tan J: The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation 2: 24, 2005. PMID: 16259628. DOI: 10.1186/1742-2049-2-24

12 Ginhoux F, Lim S, Hoefl G, Low D and Huber T: Origin and differentiation of microglia. Front Cell Neurosci 7: 45, 2013. PMID: 23616747. DOI: 10.3389/fncel.2013.00045

13 London A, Cohen M and Schwartz M: Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci 7: 34, 2013. PMID: 23596391. DOI: 10.3389/fncel.2013.00034
26 Hatzipetros T, Kidd JD, Moreno AJ, Thompson K, Gill A and Harraz MM, Marden JJ, Zhou W, Zhang Y, Williams A, Sharov Weydt P, Yuen EC, Ransom BR and Moller T: Increased cytotoxic Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS and Appel SH: Activated microglia initiate Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JF: Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in SOD1G93A mice. Proc Natl Acad Sci USA 103(21): 7594-7599, 2008. PMID: 18492803. DOI: 10.1073/pnas.0802556105

21 Jaarsma D, Teuling E, Haasdijk ED, DeZeeuw CI and Hoogenraad CC: Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci 28(9): 2075-2088, 2008. PMID: 18305242. DOI: 10.1523/JNEUROSCI.5258-07.2008

23 Alexianu ME, Kozovska M and Appel SH: Mutant SOD (G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem 98(2): 179-182, 2003. PMID: 15378658. DOI: 10.1002/jn.48062.

27 Liao B, Zhao W, Beers DR, Henkel JS and Appel SH: Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 237(1): 147-152, 2012. PMID: 22735487. DOI: 10.1016/j.expneurol.2012.06.011

28 Brettschneider J, Toledo JB, Van Deelen VM, Elman L, McCluskey L, Lee VM and Trojanowski JQ: Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 7(6): e39216, 2012. PMID: 22720079. DOI: 10.1371/journal.pone.039216

29 Tarhini Ahmad A, Belani Chandra, Luketich James D, Ramalingam Suresh S, Argiris Athanasians, Gooding William, Pennathur A, Petro D, Kane K, Liggitt D, Championsmith T, Zhang X, Epperly MW and Greenberger JS: A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase (MnSOD) plasmid liposome (PL) protection in patients with locally advanced stage III non-small cell lung cancer. Hum Gene Ther 22(3): 336-343, 2011. PMID: 20873987. DOI: 10.1089/hum.2010.078

30 Ferraiuolo L, Meyer K, Sherwood TW, Vick J, Likhite S, Frakes A, Miranda CJ, Braun L, Heath PR, Pineda R, Beattie CE, Shaw PJ, Askwith CC, McGtigue D and Kaspar BK: Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci USA 113(42): E6946-E6505, 2016. PMID: 27688759. DOI: 10.1073/pnas.1607496113

31 Buttereit A, Lelios I, Yu X, Vrohlinges M, Krakoski NR, Gautier EL, Nishinakamura R, Becher B and Greter M: Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol 17: 1397-1406, 2016. PMID: 27776109. DOI: 10.1038/ni.3585

32 Taylor JP, Brown, Jr. RH and Cleveland DW: Decoding ALS: from genes to mechanism. Nature 539: 197-206, 2016. PMID: 27830784. DOI: 10.1038/nature20413

33 Falkner S, Grade S, Dimou L, Conzelmann K-K, Bonhoeffer T, Gotz M and Hubener M: Transplanted embryonic neurons integrate into adult neocortical circuits. Nature 539: 248-253, 2016. PMID: 27773592. DOI: 10.1038/nature20113

34 Sunico CR, Sultan A, Nakamura T, Dolatabadi N, Parker J, Shan B, Han X, Yates JR 3rd, Masliah E, Ambasudhan R, Nakanishi N and Lipton SA: Role of sulfiredoxin as a peroxiredoxin-2 dentrolysin in human iPS-derived dopaminergic neurons. Proc Natl Acad Sci USA 113: E7564-E7571, 2016. PMID: 27821734. DOI: 10.1073/pnas.1608784113

35 Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham T, Mathys H, Seo J, Kritskiy O, Abdulrrob Or, Adaiakkan C, Canter RG, Rueda R, Brown EN, Boyden ES and Tsai LH: Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540: 230-235, 2016. PMID: 27299004. DOI: 10.1038/nature20587

36 Lecuver M-A, Saint-Laurent O, Bourbonniere L, Larouche S, Lecuyer M-A, Saint-Laurent O, Bourbonniere L, Larouche S, Haghayegh Jahromi N, Gowing E, Pittet C, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES and Tsai LH: Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540: 230-235, 2016. PMID: 27299004. DOI: 10.1038/nature20587
38 Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B and Barres BA: Neurototoxic reactive astrocytes are induced by activated microglia. Nature 541: 481-487, 2017. PMID: 28999414. DOI: 10.1038/nature21029

39 Velasco S, Ibrahim MM, Kakumanu A, Garipler G, Aydin B, Al-Sayegh MA, Hirsekorn A, Abdul-Rahman F, Satija R, Ohler U, Mahony S and Mazzoni EO: A multi-step transcriptional and chromatin state cascade underlies motor neuron programming from embryonic stem cells. Cell Stem Cell 20: 205-217, 2017. PMID: 27939218. DOI: 10.1016/j.stem.2016.11.006

40 Ehrlich M, Mozafari S, Glatza M, Starost L, Velychko S, Velasco S, Ibrahim MM, Kakumanu A, Garipler G, Aydin B, Al-Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B and Barres BA: Neurototoxic reactive astrocytes are induced by activated microglia. Nature 541: 481-487, 2017. PMID: 28999414. DOI: 10.1038/nature21029

41 Chang J, Mancuso MR, Maiar C, Liang X, Yuki K, Yang L, Kwong JW, Wang J, Rao V, Vallon M, Kosinski C, Zhang J, Mah AT, Xu L, Li J, Gholamian S, Reyes TF, Li R, Kuhnt T, Han X, Yuan J, Chiu SH, Brettman AD, Daly L, Corney DC, Cheshier SH, Shortliffe LD, Wu X, Snyder M, Chan P, Giffard RG, Chang HY, Andreasson K and Kuo CJ: Gpr124 is essential for blood–brain barrier integrity in central nervous system disease. Exp Neurol 242-249, 2014. PMID: 25254338. DOI: 10.1016/j.expneurol.2014.12.011

42 Haidet-Phillips AM and Maragakis NJ: Human glial progenitor engrafment and gene expression is independent of the ALS environment. Exp Neur 264: 343-350, 2015. PMID: 25523812. DOI: 10.1016/j.expneurol.2014.12.011

43 Haidet-Phillips AM and Maragakis NJ: Neural and glial progenitor transplantation as a neuroprotective strategy for amyotrophic lateral sclerosis (ALS). Brain Res 1628: 343-350, 2015. PMID: 26187754. DOI: 10.1016/j.brainres.2015.06.035

44 Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S and Inoue H: Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of SOD1G93A mice. Stem Cell Reports 3: 242-249, 2014. PMID: 25254338. DOI: 10.1016/j.stemcr.2014.05.017

45 Chen H, Qian K, Chen W, Hu B, Blackbourn, IV LW, Du Z, Ma L, Liu H, Knobel KM, Ayala M and Zhang SC: Human-derived neural progenitors functionally replace astrocytes in adult mice. J Clin Invest 125(3): 1033-1043, 2015. PMID: 25642771. DOI: 10.1172/JCI69007

46 Nicaise C, Mitrecic D, Falnikar A and Lepore AC: Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury. World J Stem Cells 7(2): 380-398, 2015. PMID: 25815122. DOI: 10.4252/wjsc.v7.i12.380

47 Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, Wang Y, Zhong Z, Sullivan JS, Griffin JH, Cleveland DW and Zlokovic BV: Blood–spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci USA 11(11): E1035-E1042, 2014. PMID: 24591593. DOI: 10.1073/pnas.1401595111

48 Haessler AR, Donnelly CJ and Rothstein JD: The expanding biology of the Chor72 nucleus repeat expansion in neurodegenerative disease. Nature Rev Neurosci 17(6): 383-395, 2016. PMID: 27150398. DOI: 10.1038/nrn.2016.38

49 Hill-Kayser CE, Plastaras JP, Tochner Z and Glaitstein E: TBI during BM and SCT: review of the past, discussion of the present, and consideration of future directions. Bone Marrow Transplant 46: 475-484, 2011. PMID: 21113184. DOI: 10.1038/bmt.2010.280

50 Schneideman J, Thomann K and Kletzel M: Correction of enzyme levels with allogeneic hematopoietic progenitor cell transplantation in Niemann-Pick type B. Pediatr Blood Cancer 49(7): 987-989, 2007. PMID: 17635007. DOI: 10.1002/pbc.21300

51 Appel SH, Engelhardt JH, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK and Popat U: Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17): 1326-1334, 2008. PMID: 18936424. DOI: 10.1212/01.wnl.0000276683.43541.22

52 Ohnishi S, Ito H, Suzuki Y, Adachi Y, Wate R, Zhang J, Nakano S, Kusaka H and Ikekura S: Intra-bone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis. Brain Res 1296: 216-224, 2009. PMID: 19866707. DOI: 10.1016/j.brainres.2009.08.012

53 Van der Kogel AJ: Dose-volume effects in the spinal cord. Radiother Oncol 29(2): 105-109, 1993. PMID: 8310135.

54 Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largesaap DA and Verfaillie CM: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418: 41-49, 2002. PMID: 12077603. DOI: 10.1038/nature00870

55 Morikawa S, Mabuchi Y, Kubota Y, Nagai Y, Niibe K, Hiratsu H, Suzuki S, Miyauchi-Hara C, Nagoshi N, Sunabari T, Shimamura S, Miyawaki A, Nakagawa T, Suda T, Okano H and Matsuzaki Y: Prospective identification, isolation, and systematic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 206(11): 2493-2496, 2009. PMID: 19481085. DOI: 10.1084/jem.20091046

56 Yu H, Shen H, Yuan Y, XuFeng R, Hu X, Garrison SP, Zhang L, Yu J, Zambetti GP and Cheng T: Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose γ-irradiation. Blood 115: 3472-3480, 2010. PMID: 20177048. DOI: 10.1182/blood-2009-10-248278

57 Gowing G, Philips T, Van Wijmeersch B, Audet JN, Dewil M, Van Den Bosch L, Billiau AD, Robberecht W and Julien JP: Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J Neurosci 28: 10234-10244, 2008. PMID: 18842883. DOI: 10.1523/JNEUROSCI.3494-08.2008

58 Lino MM, Schneider C and Caroni P: Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 22: 4825-4832, 2002. PMID: 12077179.

59 Willis J, Epperly MW, Fisher R, Zhang X, Shields D, Hou W, Wang H, Li S, Wipf P, Parmar K, Guinan E, Steinman J and Greenberger JS: Amelioration of head and neck radiation-induced mucositis and distant marrow suppression in Fanca-/- and Fancc-/- mice by intraoral administrations of GS-nitroxide (JP4-039). Radiat Res 189: 560-578, 2018. PMID: 29584588. DOI: 10.1667/RR14878.1
Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol 29: 213-224, 2003. PMID: 12649121. DOI: 10.1165/rcmb.2002-0690OC

Amelioration of irradiation pulmonary fibrosis by a water-soluble bi-functional sulfoxide radiation mitigator (MnSOD). Radiat Res 180: 474-490, 2013. PMID: 24125487. DOI: 10.1667/RR13405.1

Continuous 1 year oral administration of the radiation mitigator, MnSOD, after total body irradiation restores bone marrow stromal cell proliferative capacity and reduces age-related senescence in Fanconi Anemia (Fanc−/−) mice. Radiat Res 191: 139-143, 2019. PMID: 30499383. DOI: 10.1667/RR15199.1

Bone marrow stromal and hematopoietic progenitor cell lines from Fanconi Anemia (Fancd2−/−) mice. Radiat Res 181(4): 76-89, 2014. PMID: 24397476. DOI: 10.1667/RR13405.1

Bone marrow stromal and hematopoietic progenitor cell lines from Fanconi Anemia (Fancd2−/−) mice. Radiat Res 181(1): 1-12, 2014. PMID: 23694376. DOI: 10.1667/RR13405.1

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.

Distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways improved total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 154(4): 365-374, 2000. PMID: 11023599.